Molecular Analysis of Breast Cancer
This is a research-based study that is looking at the biologic features of breast tissue, lymph node tissue, or blood in order to study breast cancer development growth, and spread. Through tissue and/or blood samples we hope to gain further knowledge and understanding of how to improve diagnosis and treatment of breast cancer by identifying the molecular markers that predict clinical outcome and response to therapy.
NCT00569049 — Breast Cancer
Status: Active, not recruiting
http://inclinicaltrials.com/breast-cancer/NCT00569049/
Benign Reproductive Tissue Evaluation (BRTE) Study
Background: - Endometrial cancer (cancer of the lining of the uterus) is the most common gynecologic cancer in the United States. - Currently, there are no markers (components of blood and tissue that determine who might be at risk for developing cancer) for endometrial cancer. Objectives: -To see if women who are undergoing hysterectomy are willing to provide blood and tissue samples to help doctors identify markers that would indicate increased risk for developing endometrial cancer. Eligibility: -Women between 35 and 54 years of age who will undergo hysterectomy for a non-cancerous condition, such as uterine fibroids, uterine prolapse, abnormal uterine bleeding, and others at Magee-Women's Hospital in Pittsburgh, Penn. Design: - Patients' medical records are reviewed and patients complete a questionnaire including information on race and ethnic background, education, marital status, family history, height, weight, pregnancy history, smoking history, medication history, history about menstrual periods and menopausal symptoms. - Patients provide blood and urine samples before surgery. - A sample of fat tissue is removed during surgery in patients undergoing abdominal surgery. - Tissue samples from the removed uterus (and ovaries if the ovaries are also removed) are collected and analyzed for markers for endometrial cancer.
NCT00481754 — Hysterectomy
Status: Completed
http://inclinicaltrials.com/hysterectomy/NCT00481754/
Molecular and Genetic Analysis of Lung Cancer
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This clinical trial is analyzing the DNA in blood and tissue samples from patients with lung cancer.
NCT00471978 — Lung Cancer
Status: Recruiting
http://inclinicaltrials.com/lung-cancer/NCT00471978/
The Significance of Sentinel Node Analysis in Colon Cancer
This study is for the patient with colon cancer, who is going to have colon cancer surgery. The purpose of this research study is to examine a specific lymph node, called the sentinel node. Lymph nodes are located throughout your body and cancer may spread by means of those lymph nodes. The sentinel node is the one located closest to your tumor. This study will find out if examining the sentinel node can help to predict disease progression. Since the value of this exam is unknown, taking part in this study will not change your clinical care.
NCT00419978 — Colon Cancer
Status: Terminated
http://inclinicaltrials.com/colon-cancer/NCT00419978/
A Multicenter Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.
NCT00127036 — Colon Cancer
Status: Terminated
http://inclinicaltrials.com/colon-cancer/NCT00127036/
Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study
RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine may improve the ability to detect bladder cancer without invasive procedures. PURPOSE: Diagnostic trial to study the effectiveness of microsatellite analysis of sediment in the urine in detecting bladder cancer in healthy participants, participants who have genitourinary conditions requiring cystoscopy, and patients who have bladder cancer.
NCT00095589 — Bladder Cancer
Status: Completed
http://inclinicaltrials.com/bladder-cancer/NCT00095589/
A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
NCT00075868 — Colorectal Cancer
Status: Completed
http://inclinicaltrials.com/colorectal-cancer/NCT00075868/
Total Anorectal Reconstruction With The American Medical Systems, Inc. Acticon Neosphincter Prosthesis After Abdominoperineal Resection
RATIONALE: An anal sphincter prosthesis may replace the need for a permanent colostomy and may improve the quality of life of patients who are undergoing surgery for anal or rectal cancer. PURPOSE: Clinical trial to study the effectiveness of an anal sphincter prosthesis in treating patients who have anal or rectal cancer and are undergoing surgery to remove the anus and rectum.
NCT00059891 — Colorectal Cancer
Status: Completed
http://inclinicaltrials.com/colorectal-cancer/NCT00059891/
Analysis of Prostate Cancer Short-Term Cultures Utilizing Molecular Cytogenetic Methods
This study will examine prostate tumor tissue cultures to try to identify genetic abnormalities that contribute to the cause or progression of the disease. Patients with prostate cancer enrolled in the National Cancer Institute protocol 97-C-0147 (Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Disease) may be eligible for this study. Specimens for tissue culture for this study will be obtained from tumors surgically removed from patients participating in NCI protocol 97-C-0146. The findings of this study may lead to better methods of predicting the course of disease in individual patients.
NCT00022919 — Prostate Cancer
Status: Completed
http://inclinicaltrials.com/prostate-cancer/NCT00022919/
Phase II and Pharmacokinetic Trial of Rebeccamycin Analog in Hepatobiliary Cancers
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have advanced liver and/or biliary cancer.
NCT00005997 — Liver Cancer
Status: Terminated
http://inclinicaltrials.com/liver-cancer/NCT00005997/